Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Ascending Doses of AZD4635 Both as Monotherapy and in Combination in Patients With Advanced Solid Malignancies

Next Previous
Search
Trial Profile

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Ascending Doses of AZD4635 Both as Monotherapy and in Combination in Patients With Advanced Solid Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone (Primary) ; Durvalumab (Primary) ; Enzalutamide (Primary) ; Imaradenant (Primary) ; Oleclumab (Primary) ; Docetaxel; Prednisone
  • Indications Carcinoma; Colorectal cancer; Head and neck cancer; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors AstraZeneca

    • Most Recent Events

    • 01 Apr 2024 According to a Nxera Pharma Co., Ltd. media release, Sosei Heptares name changed to Nxera Pharma Co., Ltd.
    • 25 May 2023 Status changed from active, no longer recruiting to completed.
    • 31 Aug 2022 Results (n=250; as of 8 Sep 2020) reporting toxicity from phase 1a portion of this trial published in the Clinical Cancer Research

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top